Skip to main content

Advertisement

Table 4 Delayed increase in peripheral blood cell counts for acute myeloid leukemia (AML) patients with stable disease during treatment with all-trans retinoic acid (ATRA), valproic acid and low-dose cytarabine; a comparison of pretreatment/early treatment values versus maximal levels

From: The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

  Platelet Neutrophil Erythrocyte
Patient Before or during the first 14 days Highest value during treatment Before or during the first 14 days Highest value during treatment Transfusion independent > two months
SD1 12 49 (90) 0.1 0.7 (102) yes
SD2 22 64 (273) 0.1 0.8 (77) yes
SD3 < 5 79 (55) 0.4 0.4 (74) -
SD4 103 302 (51) 0.5 0.2 (126) -
SD5 19 51 (136) < 0.1 0.3 (67) yes
SD6 55 81 (106) < 0.1 0.2 (112) -
SD7 18 30 (15) 9.8 7.2 (27) -
SD8 48 98 (40) 3.8 8.2 (473) -
SD9 28 96 (141) 2.9 1.8 (49) -
  1. The values before treatment represent the lowest value during this time. The highest value represents the value registered after the first 14 days of treatment, and the parenthesis gives the day after start of treatment when this value was registered. The units for both platelet and neutrophil counts are × 109 /L.